Influences of XDH genotype by gene–gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn’s disease

References

• Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;CD000067.
   Google Scholar
• Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;9:CD000478.
   PubMed Web of Science ®Google Scholar
• Present DH, Meltzer SJ, Krumholz MP, et al. 6Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641–649.
   PubMed Web of Science ®Google Scholar
• Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081–1085.
   PubMed Web of Science ®Google Scholar
• Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485–489.
   PubMed Web of Science ®Google Scholar
• Derijks LJ, Wong DR. Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr Pharm Des. 2010;16:145–154.
   PubMed Web of Science ®Google Scholar
• Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002;51:143–146.
   PubMed Web of Science ®Google Scholar
• Booth RA, Ansari MT, Loit E, et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med. 2011;154:814–823.
   PubMed Web of Science ®Google Scholar
• Dewit O, Moreels T, Baert F, et al. Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. Clin Biochem. 2011;44:1062–1066.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118:1025–1030.
   PubMed Web of Science ®Google Scholar
• Kim JH, Cheon JH, Hong SS, et al. Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study. J Clin Gastroenterol. 2010;44:e242–e248.
   PubMed Web of Science ®Google Scholar
• Takatsu N, Matsui T, Murakami Y, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2009;24:1258–1264.
   PubMed Web of Science ®Google Scholar
• Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999;9:37–42.
   PubMedGoogle Scholar
• Ding L, Zhang FB, Liu H, et al. Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:63–73.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Yang SK, Kim KJ, et al. The safety and efficacy of azathioprine and 6-mercaptopurine in the treatment of Korean patients with Crohn's disease. Intest Res. 2009;7:22–31.
   Google Scholar
• Lee KM, Kim YS, Seo GS, et al. Use of thiopurines in inflammatory bowel disease: a consensus statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015;13:193–207.
   PubMed Web of Science ®Google Scholar
• Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46:1017–1020.
   PubMed Web of Science ®Google Scholar
• Rashidi MR, Beedham C, Smith JS, et al. In vitro study of 6-mercaptopurine oxidation catalysed by aldehyde oxidase and xanthine oxidase. Drug Metab Pharmacokinet. 2007;22:299–306.
   PubMed Web of Science ®Google Scholar
• Al Hadithy AF, de Boer NK, Derijks LJ, et al. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis. 2005;37:282–297.
   PubMedGoogle Scholar
• Kudo M, Moteki T, Sasaki T, et al. Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet Genomics. 2008;18:243–251.
   PubMed Web of Science ®Google Scholar
• Loftus EV, Jr, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gastroenterology. 1998;114:1161–1168.
   PubMed Web of Science ®Google Scholar
• Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: a KASID study. Inflamm Bowel Dis. 2008;14:542–549.
   PubMed Web of Science ®Google Scholar
• Ye BD, Yang SK, Cho YK, et al. Clinical features and long-term prognosis of Crohn's disease in Korea. Scand J Gastroenterol. 2010;45:1178–1185.
   PubMed Web of Science ®Google Scholar
• Parks DA, Granger DN. Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol Scand Suppl. 1986;548:87–99.
   PubMedGoogle Scholar
• Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423–433.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events v.4.0, 2009; [cited 2015 Mar 5]. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
   Google Scholar
• Lewis JD, Abramson O, Pascua M, et al. Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. Clin Gastroenterol Hepatol. 2009;7:1195–1201.
   PubMed Web of Science ®Google Scholar
• Su WH, Yao Shugart Y, Chang KP, et al. How genome-wide SNP-SNP interactions relate to nasopharyngeal carcinoma susceptibility. PLoS One. 2013;8:e83034
   PubMed Web of Science ®Google Scholar
• Hawwa AF, Millership JS, Collier PS, et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol. 2008;66:517–528.
   PubMed Web of Science ®Google Scholar
• Wroblova K, Kolorz M, Batovsky M, et al. Gene polymorphisms involved in manifestation of leucopenia, digestive intolerance, and pancreatitis in azathioprine-treated patients. Dig Dis Sci. 2012;57:2394–2401.
   PubMed Web of Science ®Google Scholar
• Cordell HJ. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet. 2002;11:2463–2468.
   PubMed Web of Science ®Google Scholar
• Sarlos P, Varszegi D, Csongei V, et al. Susceptibility to ulcerative colitis in Hungarian patients determined by gene-gene interactions. World J Gastroenterol. 2014;20:219–227.
   PubMed Web of Science ®Google Scholar
• Johnson JD, Mehus JG, Tews K, et al. Genetic evidence for the expression of ATP- and GTP-specific succinyl-CoA synthetases in multicellular eucaryotes. J Biol Chem. 1998;273:27580–27586.
   PubMed Web of Science ®Google Scholar
• Elpeleg O, Miller C, Hershkovitz E, et al. Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. Am J Hum Genet. 2005;76:1081–1086.
   PubMed Web of Science ®Google Scholar
• Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmaco Therap. 2006;24:331–342.
   PubMed Web of Science ®Google Scholar